SOST and osteoporosis: Langdahl Langdahl BL BL Libanati Libanati C C Crittenden Crittenden DB DB Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial Lancet Lancet 2017 2017 390 390 1585 1585 1594 1594 10.1016/S0140-6736(17)31613-6 10.1016/S0140-6736(17)31613-6 28755782 28755782